Variables | HC | T2D | t/Z /χ2 value | p value |
---|---|---|---|---|
n | 89 | 115 | − | − |
Female, n (%) | 47 (52.8) | 42 (36.5) | 5.412 | 0.020 |
Age (years) | 55.06 ± 8.82 | 55.32 ± 11.42 | 0.128 | 0.856 |
BMI (kg/m2) | 23.00 ± 2.42 | 24.92 ± 3.81 | 4.375 | 0.001 |
WC (cm) | − | 90.80 ± 9.41 | − | − |
SBP (mmHg) | 121.53 ± 10.98 | 132.84 ± 16.39 | 5.890 | < 0.001 |
DBP (mmHg) | 78.17 ± 7.53 | 79.21 ± 10.70 | 0.823 | 0.412 |
Diabetic duration (year) | − | 8 (2−10) | − | − |
Glucose-lowering therapies | ||||
Lifestyle alone, n (%) | − | 32 (27.8) | − | − |
Insulin treatments, n(%) | − | 35 (30.4) | − | − |
Insulin secretagogues, n (%) | − | 39 (33.9) | − | − |
Metformin, n (%) | − | 53 (46.1) | − | − |
Pioglitazone, n (%) | − | 10 (8.7) | − | − |
AGIs, n (%) | − | 13 (11.3) | − | − |
GLP-1RAs, n (%) | − | 1 (0.9) | − | − |
DPP-4Is, n (%) | − | 8 (7.0) | − | − |
FPG (mmol/L) | 5.18 ± 0.48 | 11.07 ± 3.58 | 17.426 | < 0.001 |
TG (mmol/L) | 1.33(1.01 − 1.86) | 1.47 (0.96−2.84) | 1.415 | 0.157 |
TC (mmol/L) | 4.72 ± 0.72 | 4.73 ± 1.48 | 0.053 | 0.958 |
HDLC (mmol/L) | 1.45 ± 0.32 | 1.17 ± 0.31 | − 6.107 | < 0.001 |
LDLC (mmol/L) | 3.00 ± 0.62 | 2.91 ± 1.04 | − 0.737 | 0.462 |
eGFR (ml/min/1.73 m2) | 128.36(92.48−151.86) | 121.81 (90.93−146.78) | − 3.427 | 0.078 |
Serum UA (umol/L) | 295.90 ± 75.06 | 317.00 ± 115.21 | 1.532 | 0.127 |
HbA1c (%) | − | 9.60 ± 2.07 | − | − |
FABP4 (pg/ml) | 9498.46 (5168.19−14406.19) | 17535.96 (9513.62−28436.53) | 6.107 | < 0.001 |